Should You Buy This Blue Chip Dividend Stock?
Because investing is future-oriented, it is important that investors purchase businesses with ample growth potential in the years ahead. The best way to do this is to only consider investing in leaders within thriving industries.
Boasting a $62 billion market capitalization, (NYSE: HUM) is the fifth-biggest player in the healthcare plans industry. But is the stock a buy for investors in search of dividend growth? Let's peek at Humana's fundamentals and valuation and see if an answer presents itself.
Originally founded as a nursing home operator in 1961, Humana began the process of establishing itself as a health insurance plan juggernaut in the 1980s. Since that time, the company has grown its total medical, vision, and dental membership base to over 22 million as of June 30. This is especially encouraging because of the robust future that awaits the global health insurance industry due to chronic diseases becoming more common. That's why the market research firm Fortune Business Insights is forecasting that the global health insurance market will rise from $2.1 trillion in 2021 to over $3 trillion by 2028.
Source Fool.com
Humana Inc. Aktie
Die Community sieht Humana Inc. leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 186 € liegt unter dem aktuellen Kurs von 332.0 € für Humana Inc., führt aber zu einem negativen Potenzial von -43.98%.
